Amgen Provides Update on Status of Puerto Rico Operations

In the two weeks since Hurricane Maria hit Puerto Rico, Amgen has been providing support to our staff members and the local community while implementing our well-rehearsed business continuity plans to restore manufacturing operations at our site in Juncos. The company continues providing an uninterrupted supply of medicines for patients around the world.

Staff and Community
  • We are ensuring a broad safety net of resources for Amgen staff in Puerto Rico, including pay continuity, access to goods and services, and financial assistance
  • The company has activated the Amgen Staff Disaster Relief Fund which provides grants of up to $5,000 for reimbursement of expenses for shelter, transportation, medical attention and clothing
  • Amgen has mobilized resources to support our staff in Puerto Rico, providing water/ice, gas, food, care packages and banking services
  • In Juncos, the Amgen site has provided diesel fuel for generators to the local hospital, dialysis clinic and grocery store
  • The Amgen Foundation has pledged $3 million to support urgent Hurricane Maria relief efforts in Puerto Rico. The Foundation also has committed up to an additional $2 million for longer-term rebuilding efforts. The first grants from this pledge are to:
    • $1 million to Direct Relief
    • $1 million to International Medical Corps
    • $500,000 to Americares
  • Critical manufacturing areas were not significantly impacted by the storm; Clean-up and restoration efforts are underway
  • Amgen has back-up generators powering the site and regular deliveries of diesel fuel are being supplied under pre-arranged contracts
  • Some local water service has been restored, and is being supplemented by on-site wells and Amgen’s water storage tanks
  • The site has some telecommunications connectivity via satellite and microwave connections
  • We have sent the first shipments of medicines by air and sea from our inventory in Puerto Rico
  • Staff are being called back to work in waves with 40% already on site full-time
  • We are preparing to resume manufacturing in various plants, including bulk drug substance manufacturing, formulation/filling and packaging – representing the full range of manufacturing capabilities at the site – over the next several weeks
  • We are actively engaging with the U.S. Food and Drug Administration (FDA) and have confirmed that we do not anticipate an impact on patient supply and to explain the steps we are taking to restart routine production at our site. An inspection by the FDA is not required prior to resuming manufacturing
  • We are actively engaging with Puerto Rico and Federal government officials to coordinate recovery activities and highlight the importance of restoring telecommunications and power to the island.